IMAB

$0.00

(

0.00%

)
Quote details

stock

I-Mab

NASDAQ | IMAB

4.63

USD

(

0.00%

)

At Close (As of Jan 1, 1970)

$533.68M

Market Cap

-

P/E Ratio

-0.51

EPS

$6.79

52 Week High

$0.59

52 Week Low

HEALTHCARE

Sector

IMAB Chart

Recent Chart
Price Action

IMAB Technicals

Tags:

IMAB Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$375M
Selling General And Administrative $216M
Research And Development $159M
Operating Expenses $375M
Investment Income Net -
Net Interest Income $7.5M
Interest Income $7.5M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.9M
Income Before Tax -$363M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$50M
Comprehensive Income Net Of Tax -
Ebit -$375M
Ebitda -$373M
Net Income -$162M

Revenue & Profitability

Earnings Performance

IMAB Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $213M
Total Current Assets $177M
Cash And Cash Equivalents At Carrying Value $68M
Cash And Short Term Investments $68M
Inventory -
Current Net Receivables $1.2M
Total Non Current Assets $36M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $31M
Short Term Investments $105M
Other Current Assets $2.1M
Other Non Current Assets -
Total Liabilities $12M
Total Current Liabilities $8.5M
Current Accounts Payable -
Deferred Revenue -
Current Debt -
Short Term Debt $816K
Total Non Current Liabilities $3.1M
Capital Lease Obligations $3.9M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $3.9M
Other Current Liabilities $7.5M
Other Non Current Liabilities -
Total Shareholder Equity $201M
Treasury Stock -
Retained Earnings -$1.3B
Common Stock $19K
Common Stock Shares Outstanding $81M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$53M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $978K
Capital Expenditures $48K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$136M
Cashflow From Financing -$335K
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$335K
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$50M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$375M
Selling General And Administrative $216M
Research And Development $159M
Operating Expenses $375M
Investment Income Net -
Net Interest Income $7.5M
Interest Income $7.5M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.9M
Income Before Tax -$363M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$50M
Comprehensive Income Net Of Tax -
Ebit -$375M
Ebitda -$373M
Net Income -$162M

IMAB Profile

I-Mab Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

I-Mab is a leading clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the discovery and development of innovative biologics for cancer and autoimmune disorders. With a robust pipeline and strong research capabilities, I-Mab is dedicated to addressing significant unmet medical needs in both domestic and international markets. The company's strategic focus on cutting-edge therapies positions it as a key player in the biopharmaceutical sector, with the potential to drive meaningful advancements in healthcare and improve patient outcomes.

LPTX
+368.57%
$2.05
CANF
+5.00%
$0.38
ASBP
+15.77%
$0.10
NVDA
-2.80%
$181.36
ONDS
+25.33%
$7.84
PLUG
+2.63%
$2.14
WTO
-8.00%
$0.02
LOBO
+27.77%
$0.50
VHAI
-33.33%
$0.00
CHR
+0.63%
$0.04
ASST
+7.69%
$1.12
CMND
-21.84%
$0.21
OLMA
+136.38%
$20.14
TSLA
-1.87%
$401.25
F
+1.08%
$13.02
AXDX
-61.36%
$0.03
PFE
+1.47%
$25.45
SOFI
-2.95%
$26.24
BITF
+2.99%
$2.75
QUBT
+7.30%
$12.34
INTC
-1.09%
$34.33
AMZN
-4.43%
$222.55
WBD
+4.17%
$23.69
NIO
-1.64%
$5.98
GRAB
-0.18%
$5.32
DNN
-0.41%
$2.38
ACHR
+2.56%
$7.61
ETHD
-8.08%
$5.23
SNAP
+0.85%
$8.25
PLTR
-2.28%
$167.33
WULF
+8.59%
$12.00
BMNR
+4.29%
$32.28
ADAP
-15.14%
$0.05
MARA
+3.21%
$11.88
GOOGL
-0.25%
$284.28
CAN
+20.75%
$1.03
NOK
-0.30%
$6.64
AAL
+0.16%
$12.36
AAPL
0.00%
$267.44
AMD
-4.25%
$230.29
CIFR
+1.60%
$14.58
KVUE
-0.06%
$16.23
RGTI
+4.13%
$25.71
NFLX
+3.44%
$114.09
HPE
-1.55%
$20.90
BYND
-3.84%
$1.01
ABEV
-0.39%
$2.53
T
+0.51%
$25.60
TLRY
0.00%
$1.03
RIVN
+0.80%
$14.99
RMBL
+60.50%
$3.21
RIG
+1.22%
$4.13
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
IREN
+3.03%
$48.85
GPUS
+0.84%
$0.24
RR
+3.84%
$3.24
BAC
+0.31%
$51.64
SRM
+53.27%
$10.30
KXIN
+2.14%
$0.29
RUBI
-4.22%
$0.16
BURU
-5.42%
$0.20
CLF
+2.00%
$11.19
MSFT
-2.69%
$493.79
PLTD
+2.29%
$7.12
MU
-5.55%
$228.50
CRWV
-0.57%
$74.90
LFS
+68.39%
$6.50
SOUN
+0.87%
$11.53
APLT
+4.99%
$0.29
QS
+0.15%
$12.97
BTBT
+3.47%
$2.38
EPSM
+91.54%
$2.72
GOOG
-0.22%
$284.96
BBD
-0.55%
$3.60
PCG
-1.10%
$16.15
ONFO
+11.48%
$0.94
BTG
0.00%
$3.99
BTE
+3.97%
$3.14
WLGS
-5.57%
$0.04
HOOD
-1.44%
$114.30
MRK
+3.84%
$96.43
SMCI
+2.34%
$34.90
MTSR
-0.35%
$70.50
TWOH
+4.16%
$0.00
QBTS
+0.43%
$22.93
IONZ
-5.35%
$4.77
AMCR
+0.11%
$8.46
DVLT
-6.16%
$1.75
APLD
-0.41%
$22.84
EOSE
+3.69%
$13.48
HIMS
+1.91%
$36.26
HBAN
+0.32%
$15.35
VALE
0.00%
$12.17
CGTL
-11.32%
$0.71
NBIS
+5.30%
$90.54
CLSK
+1.88%
$10.81
PLTZ
+4.50%
$7.42
CSCO
-0.52%
$77.37
RXRX
+0.97%
$4.16
LPTX
+368.57%
$2.05
CANF
+5.00%
$0.38
ASBP
+15.77%
$0.10
NVDA
-2.80%
$181.36
ONDS
+25.33%
$7.84
PLUG
+2.63%
$2.14
WTO
-8.00%
$0.02
LOBO
+27.77%
$0.50
VHAI
-33.33%
$0.00
CHR
+0.63%
$0.04
ASST
+7.69%
$1.12
CMND
-21.84%
$0.21
OLMA
+136.38%
$20.14
TSLA
-1.87%
$401.25
F
+1.08%
$13.02
AXDX
-61.36%
$0.03
PFE
+1.47%
$25.45
SOFI
-2.95%
$26.24
BITF
+2.99%
$2.75
QUBT
+7.30%
$12.34
INTC
-1.09%
$34.33
AMZN
-4.43%
$222.55
WBD
+4.17%
$23.69
NIO
-1.64%
$5.98
GRAB
-0.18%
$5.32
DNN
-0.41%
$2.38
ACHR
+2.56%
$7.61
ETHD
-8.08%
$5.23
SNAP
+0.85%
$8.25
PLTR
-2.28%
$167.33
WULF
+8.59%
$12.00
BMNR
+4.29%
$32.28
ADAP
-15.14%
$0.05
MARA
+3.21%
$11.88
GOOGL
-0.25%
$284.28
CAN
+20.75%
$1.03
NOK
-0.30%
$6.64
AAL
+0.16%
$12.36
AAPL
0.00%
$267.44
AMD
-4.25%
$230.29
CIFR
+1.60%
$14.58
KVUE
-0.06%
$16.23
RGTI
+4.13%
$25.71
NFLX
+3.44%
$114.09
HPE
-1.55%
$20.90
BYND
-3.84%
$1.01
ABEV
-0.39%
$2.53
T
+0.51%
$25.60
TLRY
0.00%
$1.03
RIVN
+0.80%
$14.99
RMBL
+60.50%
$3.21
RIG
+1.22%
$4.13
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
IREN
+3.03%
$48.85
GPUS
+0.84%
$0.24
RR
+3.84%
$3.24
BAC
+0.31%
$51.64
SRM
+53.27%
$10.30
KXIN
+2.14%
$0.29
RUBI
-4.22%
$0.16
BURU
-5.42%
$0.20
CLF
+2.00%
$11.19
MSFT
-2.69%
$493.79
PLTD
+2.29%
$7.12
MU
-5.55%
$228.50
CRWV
-0.57%
$74.90
LFS
+68.39%
$6.50
SOUN
+0.87%
$11.53
APLT
+4.99%
$0.29
QS
+0.15%
$12.97
BTBT
+3.47%
$2.38
EPSM
+91.54%
$2.72
GOOG
-0.22%
$284.96
BBD
-0.55%
$3.60
PCG
-1.10%
$16.15
ONFO
+11.48%
$0.94
BTG
0.00%
$3.99
BTE
+3.97%
$3.14
WLGS
-5.57%
$0.04
HOOD
-1.44%
$114.30
MRK
+3.84%
$96.43
SMCI
+2.34%
$34.90
MTSR
-0.35%
$70.50
TWOH
+4.16%
$0.00
QBTS
+0.43%
$22.93
IONZ
-5.35%
$4.77
AMCR
+0.11%
$8.46
DVLT
-6.16%
$1.75
APLD
-0.41%
$22.84
EOSE
+3.69%
$13.48
HIMS
+1.91%
$36.26
HBAN
+0.32%
$15.35
VALE
0.00%
$12.17
CGTL
-11.32%
$0.71
NBIS
+5.30%
$90.54
CLSK
+1.88%
$10.81
PLTZ
+4.50%
$7.42
CSCO
-0.52%
$77.37
RXRX
+0.97%
$4.16

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.